What is the main purpose of this 8-K filing?

This 8-K filing's primary purpose is to announce Amgen Inc.'s unaudited financial results for the second quarter and the first half of 2011, as well as its financial position as of June 30, 2011. It includes a press release detailing these results and providing extensive reconciliations between GAAP and non-GAAP financial measures.

Why does Amgen provide non-GAAP financial measures?

Amgen provides non-GAAP financial measures to offer investors supplementary information that they believe facilitates additional analysis and comparisons. These measures exclude certain items that Amgen deems may obscure the underlying operational performance, such as acquisition-related costs, stock option expensing, and certain transaction-specific charges.

What types of expenses are typically excluded in Amgen's non-GAAP reporting?

Common exclusions in Amgen's non-GAAP reporting include the impact of expensing stock options, amortization of certain acquired intangible assets (related to acquisitions like Immunex and R&D technology), costs related to recent acquisitions, accelerated depreciation, legal settlements, cost savings initiatives, and non-cash interest expense related to convertible notes.

Are these non-GAAP measures a substitute for GAAP results?

No, Amgen explicitly states that its non-GAAP financial measures are presented in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Investors should always consider both GAAP and non-GAAP figures.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on July 29, 2011, to report its unaudited financial results for the second quarter and first half of 2011. The filing primarily consists of a press release detailing these results and providing extensive reconciliations of non-GAAP financial measures to GAAP. These non-GAAP measures are presented by Amgen to offer investors supplementary insights into the company's financial performance and condition, excluding various items such as acquisition-related costs, stock-based compensation impacts, accelerated depreciation, legal settlements, and accounting adjustments for convertible notes. Investors should note that while Amgen believes these non-GAAP measures facilitate comparisons and provide a clearer view of ongoing operational performance, they are not a substitute for GAAP figures. The company has detailed various adjustments made for the periods ending June 30, 2011, and comparable periods in 2010, including specific charges and credits related to past acquisitions (Avidia, Immunex, Abgenix, Bergamo, BioVex), the BI Fremont transaction, and cost-saving initiatives. The focus remains on providing investors with tools to analyze performance trends, particularly concerning profitability and earnings per share.

Key Highlights

1Amgen announced its unaudited financial results for the three and six months ended June 30, 2011.
2The company presented both GAAP and a comprehensive set of non-GAAP financial measures, explaining the rationale for each adjustment.
3Key adjustments in non-GAAP measures include the impact of stock option expensing, acquisition-related costs (Avidia, Immunex, Abgenix, Bergamo, BioVex), and specific transaction charges (BI Fremont Transaction).
4Non-GAAP measures also exclude amortization of certain acquired intangible assets (Immunex, R&D Technology), legal settlements, cost savings initiatives, and non-cash interest expenses.
5Amgen aims to provide investors with supplemental information to facilitate comparisons across periods, particularly by excluding items that may distort underlying operational performance.
6The filing includes a detailed reconciliation of non-GAAP financial measures to their most directly comparable GAAP measures, as required by SEC regulations.
7The report highlights specific accounting treatments for convertible notes and their impact on reported debt and interest expense.

AMGEN INC 8-K Report, Financial Results (Jul 29, 2011)

Summary

Key Highlights

Frequently Asked Questions